CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 24 enrolled / 24 target
Drug / intervention
BI 764198 (C-14) (approach 1) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05863130
NCT05863130Phase 1CompletedOn Track (0.6/mo)Completion was 31mo ago
CompareCT.gov

A Phase I, Open-label, Two-arm, Non-randomised Trial to Investigate the Metabolism and Pharmacokinetics of a Single Dose of BI 764198 (C-14) Administered as Oral Solution Using Two Different Approaches in Healthy Male Volunteers

Boehringer Ingelheim·interventional·Posted May 17, 2023·Updated Jun 29, 2026

In Brief

A Phase 1 clinical trial evaluating BI 764198 (C-14) (approach 1) and BI 764198 (C-14) (approach 2) for Healthy. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The main objective of this trial is to investigate the basic pharmacokinetics of BI 764198 and its metabolites, total radioactivity including mass balance, excretion pathways and metabolism following oral administration to healthy male volunteers of a single oral dose of BI 764198 (C-14) in i) a classical hADME approach and ii) a hADME microtracer approach.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesNetherlands
Collaborators--

Timeline

Phase 1CompletedFinished
202420252026
First PostedMay 17, 2023
Enrollment StartMay 3, 2023
Primary CompletionNov 9, 2023
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 3.1 years ago

Arms & Interventions

BI 764198 (C-14) (approach 1)experimental

Drug: BI 764198 (C-14) (approach 1)
BI 764198 (C-14) (approach 2)experimental

Drug: BI 764198 (C-14) (approach 2)

Interventions

BI 764198 (C-14) (approach 1)drug

BI 764198 (C-14) (approach 1)

BI 764198 (C-14) (approach 2)drug

BI 764198 (C-14) (approach 2)